January/February 2024

Rimegepant, the first in a new class of gepants, is now available for acute and prophylactic migraine treatment in adults.

Recent evidence supports the benefits of lipid-lowering therapy for older people, suggesting chronological age alone should not be a barrier to its use.

New therapies are emerging to reduce the adverse cardiovascular outcomes and progression of chronic kidney disease in type 2 diabetes. All patients with diabetes should be screened for diabetic kidney disease and, where possible, considered candidates for therapy.

Interstitial lung disease is characterised by a diverse spectrum of disease and is often associated with significant morbidity and mortality. The PBS criteria for antifibrotic therapy now include all progressive phenotypes, emphasising the importance of early disease recognition and referral to a respiratory specialist for further management.

A woman aged 69 years presents with a perianal plaque of five months’ duration. What is the cause?